Skip to main content

Table 1 Characteristics of the patients according system involvement of the whole cohort n = 56

From: Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy

VariableOverall n = 56°Respiratory involvement n = 17Systemic involvement n = 24Digestive involvement n = 8Neurological N = 4
Age in years, Median (IQR)*39 (31–47)39 (31–47)38 (31–50)35 (28–42)36 (34–51)
Sex, male n, (%)44 (79)13 (78)21 (87)7 (88)1 (25)
On HAART**, yes n, (%)14 (25)1 (6)7 (29)5 (63)4 (100)
Fever n, (%)33 (59)12 (71)18 (75)1 (13)2 (50)
ICU admission n, (%)19 (34)8 (47)7 (30)1 (13)2 (50)
Mechanical Ventilation, yes n, (%)12 (21)6 (35%)3 (13)1 (13)1 (25)
Mortality n, (%)10 (18%)3 (18%)4 (17)1 (13)1 (25)
Cd4 cells/mm3, Median (IQR)*47 (18–85)19 (10–45)63 (22–97)67 (43–206)23 (14–69)
Cd8 cells/mm3, Median (IQR)*514 (272–828)356 (189–860)514 (289–653)727 (494–941)319 (123–649)
HIV viral load cop/ml × 105 Median, (IQR)*2.84 (0.5–6.8)1.27 (0.49–4.03)3.1 (0.8–9.1)6.6 (0.95–18.4)1.21 (0.1–4.8)
CMV*** blood VL Median (IQR)*copies/ml × 1033.7 (1.09–24.9)3.9 (1.2–43.6)1.2 (0.7–13)1.2 (0.56–31.1)0.4 (0.1–122)
LDH° IU/L values [< 240], Median (IQR)*657 (463–1000)891 (597–1333)650 (427–809)578 (441–865)430 (351–454)
  1. *Interquartile range. ** Highly active retroviral activity ***Cytomegalovirus °Lactate dehydrogenate. °Three patients were not included (1 cardiac, dermatologic and hematological involvement)